An Introduction to Alopecia Areata
Alopecia areata (AA) is an inflammatory cause of unpredictable, patchy hair loss that affects up to 2% of the population. Current treatment options for AA involve local steroid injections at the site of alopecia, combined with topical retinoids, but these are of limited efficacy and are associated with significant adverse effects. Recent insights into the pathogenesis of AA have allowed the development of novel treatment options, in particular Janus kinase (JAK) inhibitors and cytokine-targeted therapy. There have also been reports of hair regrowth following treatment with platelet-rich plasma, stem cell-based therapy approaches and faecal microbiota transplantation.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Alopecia Areata Content
Understanding alopecia areata: Current perspectives and emerging therapies for a complex disease
Watch two expert dermatologists discuss AA, focusing on issues related to disease severity, pathophysiology and treatment with JAK inhibitors.
- Recognize the risk factors, symptoms, and burden of alopecia areata
- Describe the pathophysiology and immunological mechanisms involved in alopecia areata
- Evaluate how emerging therapies for alopecia areata may be incorporated into the current landscape and change clinical practice
Brett King, EADV 2021: JAK Inhibitors in the Treatment of Alopecia Areata
It was an absolute pleasure to be able to speak with Dr Brett King (Yale School of Medicine, New Haven, CT, USA) about the recent efficacy and safety results presented around the JAK inhibitors, baricitinib and ritlecitinib, in the treatment of alopecia areata. His presentations entitled ‘Efficacy and Safety of Ritlecitinib (PF-06651600) in Patients with […]
William Damksy: Hot Topics in Alopecia Areata
touchIMMUNOLOGY caught up with William (Bill) Damsky (Yale School of Medicine, New Haven, CT, USA) to discuss hot topics and current educational needs in the treatment of alopecia areata. Disclosures: William Damsky is a consultant for Eli Lilly, Pfizer, and TWi Biotechnology; has received research funding from Pfizer and receives licensing fees from EMD, Millipore […]
William Damsky: BRAVE AA1 Study Results
touchIMMUNOLOGY caught up with William (Bill) Damsky (Yale School of Medicine, New Haven, CT, USA) to discuss the results from the BRAVE AA1 study (NCT03570749) investigating the use of baricitinib in the treatment of alopecia areata. Questions What is the rationale for the use of JAK inhibitors in the treatment of alopecia areata? (0:12) Could […]
New Perspectives in the Treatment of Alopecia Areata
Alopecia areata (AA) is a common dermatological disorder characterized by hair loss of the scalp and/or body, which is often resistant to treatment. It has a substantial impact on body image and self-esteem, resulting in greatly reduced quality of life.1 Its pathogenesis has not been fully elucidated, although increasing evidence suggests that it is a […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!